nucleosides (25) . The dxA nucleoside is a violet-blue fluorophore with emission maximum at 389 nm (26) , and the dxT nucleoside is also violet, with emission at 375 nm. Separate experiments confirmed that both are fluorescent in the context of oligomers. Thus all the base pairs of xDNA are fluorescent, which suggests applications in detection and analysis of natural DNA and RNA.
When all expanded base analogs are placed in one strand, it allows the targeting of natural DNA with enhanced binding affinity. This suggests the use of expanded oligomers (xDNAs) in applications involving hybridization, such as with microarrays, antisense studies, and analytical DNA/RNA detection methods. It remains to be tested whether analogous expanded guanine and cytosine analogs would pair similarly in this context, which would be necessary for generalized targeting of any natural sequence.
We conclude that a genetic base-paired molecular framework is not limited to the size of the DNA helix that evolved in terrestrial biology. It is noteworthy that one significant difference of this expanded-size genetic system, relative to the natural one, is its increased potential for encoding information (27) . Pairing of four expanded bases with the four natural bases in all complementary combinations would be expected to yield eight base pairs of information encoding ability. Sc accumulation in prion-infected cells in culture have only modest effects in vivo on disease incubation periods in prion-infected mice and only when coadministered with the prion inoculum or very soon after infection (8, 9) . No treatment has been effective in animals after the onset of clinical signs of disease, and no agent has prevented disease progression in mice during the asymptomatic preclinical phase of central nervous system (CNS) scrapie infection, when intervention would have the greatest therapeutic potential (10, 11) . The conversion of PrP c to PrP
Sc is intrinsic to the pathological process, however, because mice devoid of PrP c (Prnp 0/0 ) are resistant to prion disease and do not propagate infectivity (1, 2, 12) . Similarly, PrP-null brain tissue surrounding prion-infected Prnp ϩ/ϩ neurografts does not develop prion neuropathological change (7) . Targeting PrP c itself, as opposed to PrP Sc , in established prion infection directly removes the substrate for further conversion and prion replication and might be expected to be a more effective therapeutic strategy than reduction of PrP Sc accumulation. We tested the effects of neuronal PrP c depletion in animals with established neuroinvasive scrapie on the subsequent course of disease and neuropathological changes. We have previously shown that acquired neuronal PrP c depletion in adult mice is in itself without major detrimental effects (13) . In another mouse model of acquired PrP knock-out, only the effects of PrP c depletion before inoculation with scrapie prions were studied (14) , essentially replicating the inoculation of Prnp 0/0 animals; the effects of PrP c depletion after scrapie infection were not examined. We used two lines of transgenic MloxP mice, tg37 and tg46, that express PrP c from MloxP transgenes at ϳ3 and 1 times wild-type levels, respectively, and that normally succumb to scrapie ϳ12 and 18 weeks, respectively, after intracerebral Rocky Mountain Laboratory (RML) scrapie prion inoculation ( Figs. 1 and 2 ). PrP c expression in these mice (which were generated on a Prnp 0/0 background) can be eliminated by the action of S1 ). Thus, double transgenic NFH-Cre/MloxP mice express PrP in neurons and nonneuronal cells until ϳ12 weeks of age, when they undergo Cre-mediated depletion of neuronal PrP c (13). We inoculated NFH-Cre/MloxP mice with RML scrapie prions at 3 to 4 weeks of age on weaning, allowing prion replication and CNS infection to proceed normally until Cre-mediated neuronal PrP c depletion occurred. MloxP mice without the NFH-Cre transgene were inoculated in parallel. Animals were examined daily and were culled for analysis of neuropathological changes at two-week intervals after inoculation (17) . We confirmed MloxP transgene recombination in the brains of double transgenic animals by Southern analysis of whole-brain DNA at around 8 weeks postinoculation (wpi) ( fig. S2 ), at which stage they were 11 to 12 weeks old, consistent with our previous findings (13) . Correspondingly, total brain PrP expression, determined by semiquantitative immunoblotting (17) , was similar in all mice before 8 wpi, at which point it declined in animals with Cremediated recombination ( fig. S3 ).
At this time point, all animals with and without Cre expression showed pathological evidence of neuroinvasive CNS scrapie infection to a similar extent. Specifically, there was PrP Sc deposition and reactive astrocytosis in thalamus, hippocampus, and cortex (Fig. 3 , E, G, Q, and U). In scrapie-infected NFH-Cre/tg37 and tg37 mice (but not in tg46 mice), there was also early spongiform degeneration, notably in the hippocampus (Figs. 1 and 3 , A, C, I, and M). The early appearance of spongiosis in these animals may reflect the higher level of expression of PrP c and short scrapie incubation period of tg37 mice compared with tg46 mice. Similar levels of PrP Sc were also found in all mice at 8 wpi with the use of semiquantitative immunoblotting, but were just within the limits of detection with the use of conventional methods, and were confirmed by sodium phosphotungstic acid precipitation of PrP Sc from brain homogenates (17, 18) (fig. S4 ).
The depletion of neuronal PrP c in animals with established CNS scrapie prevented progression to clinical prion disease and resulted in the long-term survival of infected animals. To date, prion-infected NFH-Cre/tg37 and NFH-Cre/tg46 mice remain asymptomatic at Ͼ57 wpi (n ϭ 6) and Ͼ58 wpi (n ϭ 3), respectively, whereas tg37 and tg46 mice infected at the same time died after 12 weeks (84 Ϯ 5 days, n ϭ 6) and 18 weeks (120 Ϯ 2 days, n ϭ 8), respectively ( Figs. 1 and  2 ). This represents a Ͼfourfold increase in scrapie incubation time for NFH-Cre/tg37 animals (ϳthreefold for NFH-Cre/tg46 mice), approaching the normal life-span of a mouse.
Neuropathologically, asymptomatic prioninfected animals with PrP c depletion were protected from neuronal loss up to 48 wpi. In scrapie-infected tg37 mice without PrP depletion, hippocampal CA1 to CA3 neurons began to degenerate from 10 wpi, with almost complete CA1 to CA3 cell loss by 12 wpi and accompanying shrinkage of the entire hippocampus (Fig. 3, B and D) . Similar changes were seen in terminally ill tg46 mice by 18 wpi, establishing a correlation between development of clinical symptoms in RML scrapie infection and neuronal loss in MloxP mice. In contrast, in scrapie-infected NFH-Cre/MloxP mice, CA1 to CA3 neurons remained healthy, and hippocampal structure was completely preserved (Fig. 3,  I to L and M to P), demonstrating the neuroprotection afforded by depleting neuronal PrP c in established CNS scrapie infection.
Further, the hippocampus was also free of spongiosis (intraneuronal vacuoles in cells that
have not yet degenerated) in scrapie-infected mice after neuronal PrP c depletion. We found early spongiform change in both tg37 and NFHCre/tg37 mice at 8 wpi (Figs. 1 and 3 , C and M) but not in age-matched uninfected controls ( fig.  S5 ) nor in mice with Cre-mediated neuronal PrP c depletion examined as early as 10 wpi, up to 48 wpi (Figs. 1 and 3, N, O, and P, and fig. S5 ). Thus it appears that there was reversal of early (19) to allow more time for development of prion pathology before PrP c depletion. Under these conditions, there was unequivocal spongiform change at 8 wpi (Fig. 3, C and M) , which similarly reversed when Cre was expressed at the relatively later time point of 10 wpi in these animals, when they were aged ϳ11 weeks ( fig. S5) . Although in this model early spongiosis was not associated with the diagnostic neurological signs of murine scrapie, in humans this stage of prion infection may correspond to the early clinical stages of disease, which may be relatively prolonged and where any potential for reversal of pathology would be most important.
The pattern of neuroprotection observed in scrapie-infected NFH-Cre/MloxP mice correlated well with the known pattern of Cre expression in NFH-Cre mice (13) , being strongest in neuron-rich regions, in particular in the entire hippocampus. A degree of spongiform change was seen in these mice in other brain regions at late time points, notably in some cortical regions, deep white matter tracts, and cerebellum, and may reflect lower density neuronal populations and hence less overall NFH-Cre transgene expression in these regions. Importantly, however, these mice remained asymptomatic (Fig. 1) .
However, we did observe increasing gliosis and PrP Sc deposition in infected animals after PrP c depletion. Most notably, PrP Sc accumulation progressed over prolonged periods of observation (Fig. 3 , Q to T) and was clearly detected by immunoblotting in NFH-Cre/tg37 mice at 12 wpi, and in NFH-Cre/tg46 mice by 18 wpi (Fig. 4) , but was not associated with neuronal loss or clinical symptoms. In NFHCre/tg46 mice, levels of PrP Sc increased significantly by 49 wpi (Fig. 4A) , and, in NFH-Cre/ tg37 mice, PrP Sc levels at 48 wpi were equivalent to those seen in terminally ill tg37 mice at 12 wpi and in end-stage RML-scrapieinoculated wild-type mice (Fig. 4B) .
The continued accumulation of PrP Sc in this model after neuronal PrP c depletion is likely to reflect prion replication predominantly in glial cells where Cre was not expressed ( fig. S1 ) and PrP c not depleted: Both microglia (20) and astrocytes (21) (22) (fig. S5) [the predominant genetic background of these transgenic lines (13)], but here we found continued astrocytic proliferation in all animals with a notable increase over time (Fig. 3, U to X) , in parallel to and correlating with the pattern of continued PrP Sc deposition (Fig. 3, Q 
to T). We found that PrP
Sc deposits colocalized with astrocytes in the brains of infected mice with neuronal PrP c depletion with the use of dual immunofluorescent labeling for PrP and for the astrocytic marker glial fibrillary acidic protein (GFAP) (17), which was not seen in scrapie-infected control animals without PrP depletion (fig. S6) . The fact that these mice remain asymptomatic indicates that even extensive extraneuronal PrP Sc replication does not cause clinical disease or neurodegeneration in this model (23) . In contrast, the dramatic neuronal loss and clinical signs seen in MloxP mice, where PrP c was not depleted in neurons, suggest that it is the conversion of PrP c to disease-associated isoforms specifically within neurons that is neurotoxic.
Also, we found that after PrP c depletion the infectivity in brain homogenates from scrapieinfected NFH-Cre/MloxP lagged behind that of animals without the Cre transgene by 1 to 2 log infectious units but eventually reached maximally infectious titers by 48 wpi (table S1 and fig. S7 ). This initial lag is consistent with loss of neuronal propagation of infectivity, with subsequent predominantly astrocytic propagation of infectivity, as occurs in GFAP-PrP mice (21) . In- deed, high levels of prion infectivity are also found in microglia extracted from scrapie-infected mouse brains despite low levels of total PrP (24) .
It is possible that the rate of PrP Sc accumulation is also an important factor in development of symptomatic prion disease. In scrapie-infected wild-type and hemizygous Prnp 0/ϩ mice, levels of total PrP (PrP c and PrP Sc ) increase markedly during the course of disease, compared to basal levels of PrP expression (1). We found a similar increase in scrapie-infected tg46 mice between 8 wpi and 18 wpi (-Cre, Fig. 3A ) and tg37 mice between 8 wpi and 12 wpi (-Cre, Fig. 3B ), where the rise to end-stage levels of PrP Sc occurs in ϳ2 weeks, at which stage the mice become clinically affected and die. Total PrP levels also increase in prion-infected mice with neuronal PrP c depletion, presumably reflecting continued glial PrP Sc replication (Fig. 3, A and B, ϩCre), but the increase to end-stage levels of PrP Sc in NFH-Cre/tg37 takes ϳ36 weeks and produces no symptoms.
In conclusion, we have demonstrated an intervention that prevents the development of symptomatic prion disease in mice with established CNS scrapie infection. Sc throughout the brains of scrapie-infected mice is not pathogenic. Indeed, this may explain the lack of significant efficacy in vivo of therapeutic agents that reduce PrP Sc accumulation in vitro. It appears that the conversion of PrP c to disease-related forms must occur within neurons to be pathogenic, consistent with the possibility that a toxic intermediate is generated within neurons during the conversion process (4). These findings provide a rationale for targeting PrP c as a therapeutic intervention in prion disease, which could prevent the progression to clinical disease in presymptomatic individuals infected with prions or with pathogenic PRNP mutations. Sc continues to accumulate in MloxP mice after PrP c depletion and is first easily detected at 18 and 12 wpi in NFH-Cre/tg46 and NFH-Cre/tg37 brains, respectively. Samples from a terminally ill RML-inoculated wild-type mouse (ES RML) and from mock-inoculated (m.i.) NFH-Cre/MloxP mice were included as controls. kDa, kilodaltons.
